Cingulate Inc
CING
Company Profile
Business description
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.
Contact
1901 West 47th Place
KansasKS66205
USAT: +1 913 942-2300
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
13
Stocks News & Analysis
stocks
Magellan Financial Group: A dilutive acquisition of Barrenjoey
Our view of the proposed merger.
stocks
More US tech stocks look cheap as the market rotates
Meanwhile, value-leaning areas of the market, including industrials and energy stocks, are moving out of undervalued territory.
stocks
Earnings Losers: GYG, DMP & LLC slump on souring market sentiment
The results that fell short of market expectations.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,398.00 | 2.70 | -0.03% |
| CAC 40 | 8,394.32 | 186.43 | -2.17% |
| DAX 40 | 24,638.00 | 646.26 | -2.56% |
| Dow JONES (US) | 48,904.78 | 73.14 | -0.15% |
| FTSE 100 | 10,780.11 | 130.44 | -1.20% |
| HKSE | 26,059.85 | 570.69 | -2.14% |
| NASDAQ | 22,748.86 | 80.64 | 0.36% |
| Nikkei 225 | 58,057.24 | 793.03 | -1.35% |
| NZX 50 Index | 13,628.78 | 27.87 | -0.20% |
| S&P 500 | 6,881.62 | 2.74 | 0.04% |
| S&P/ASX 200 | 9,170.00 | 1.90 | 0.02% |
| SSE Composite Index | 4,182.59 | 19.71 | 0.47% |